Min Zou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Min Zou has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Vasciaveo
Department of Systems Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA
34 shared publications - Andrea Califano
Department of Systems Biology, Columbia University, New York, USA
34 shared publications - Antonio Rodriguez-Calero
Department for BioMedical Research, University of Bern, Bern, Switzerland
34 shared publications - Cory Abate-Shen
Columbia University, New York, New York
34 shared publications - Francisca Nunes de Almeida
Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center 1 Department of Molecular Pharmacology and Therapeutics New York, NY
34 shared publications - Jaime Y. Kim
Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center 1 Department of Molecular Pharmacology and Therapeutics New York, NY
34 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (7)
A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer
Although most prostate tumors are relatively indolent, advanced disease can progress to aggressive, often lethal variants, including neuroendocrine prostate cancer (NEPC). To identify drivers of aggressive prostate cancer, we used Sleeping Beauty (SB) transposon mutagenesis in a mouse model having prostate-specific loss of Pten and Tp53 (NPp53 mice). Compared with control NPp53-SB(−) mice, experimental NPp53-SB(+) mice developed more aggressive tumors with increased metastasis. Notably, NPp53-SB(+) mice exhibited NEPC phenotypes with transcriptomic features that recapitulate human NEPC. Analysis of recurrent common insertion sites (CIS) and associated genes (CIS genes) identified genes differentially expressed between NEPC and non-NEPC tumors. Analysis of NEPC-enriched CIS genes by cross-species integration of genomic and transcriptomic data prioritized sirtuin 1 (Sirt1) as a candidate mechanistic determinant of NEPC. Gain- and loss-of-function studies in human prostate cancer cells and mouse NEPC organoids confirmed that SIRT1 promotes NEPC, while pharmacological inhibition suppresses it. Thus, integration of cross-species analyses with an unbiased forward genetic screen uncovered novel drivers of NEPC.
- 28 May 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (7)
Open AccessA forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer
Although most prostate tumors are relatively indolent, advanced disease can progress to aggressive, often lethal variants, including neuroendocrine prostate cancer (NEPC). To identify drivers of aggressive prostate cancer, we used Sleeping Beauty (SB) transposon mutagenesis in a mouse model having prostate-specific loss of Pten and Tp53 (NPp53 mice). Compared with control NPp53-SB(−) mice, experimental NPp53-SB(+) mice developed more aggressive tumors with increased metastasis. Notably, NPp53-SB(+) mice exhibited NEPC phenotypes with transcriptomic features that recapitulate human NEPC. Analysis of recurrent common insertion sites (CIS) and associated genes (CIS genes) identified genes differentially expressed between NEPC and non-NEPC tumors. Analysis of NEPC-enriched CIS genes by cross-species integration of genomic and transcriptomic data prioritized sirtuin 1 (Sirt1) as a candidate mechanistic determinant of NEPC. Gain- and loss-of-function studies in human prostate cancer cells and mouse NEPC organoids confirmed that SIRT1 promotes NEPC, while pharmacological inhibition suppresses it. Thus, integration of cross-species analyses with an unbiased forward genetic screen uncovered novel drivers of NEPC.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S11 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Figure S1: Genomic alterations in prostate cancer represented in the GEMMs (related to Fig. 2). Figure S2: Additional phenotypic analyses of the GEMMs (related to Fig. 2). Figure S3: Phenotypic analysis of allograft and organoid models (related to Fig. 2). Figure S4: Additional transcriptomic analyses of the GEMMs (related to Fig. 3). Figure S5: Analyses of AR activity in GEMMS (related to Fig. 3). Figure S6: Regulatory sub-networks of the GEMM clusters (related to Fig. 3). Figure S7. MR-match of prostate cancer cells lines to human PCa (related to Figs. 5). Figure S8. Drug perturbation protein activity profiles from DU145 cells (related to Figs. 5, 6, 7). Figure S9. LNCaP Pharmacotyping to patients and GEMMs (related to Figs. 5). Figure S10: Additional validation of drug candidates (related to Figs 6, 7). Figure S11: Additional validation of drug candidates (related to Figs 6).
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S11 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Figure S1: Genomic alterations in prostate cancer represented in the GEMMs (related to Fig. 2). Figure S2: Additional phenotypic analyses of the GEMMs (related to Fig. 2). Figure S3: Phenotypic analysis of allograft and organoid models (related to Fig. 2). Figure S4: Additional transcriptomic analyses of the GEMMs (related to Fig. 3). Figure S5: Analyses of AR activity in GEMMS (related to Fig. 3). Figure S6: Regulatory sub-networks of the GEMM clusters (related to Fig. 3). Figure S7. MR-match of prostate cancer cells lines to human PCa (related to Figs. 5). Figure S8. Drug perturbation protein activity profiles from DU145 cells (related to Figs. 5, 6, 7). Figure S9. LNCaP Pharmacotyping to patients and GEMMs (related to Figs. 5). Figure S10: Additional validation of drug candidates (related to Figs 6, 7). Figure S11: Additional validation of drug candidates (related to Figs 6).
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 6. OncoLoop summary table
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 6. OncoLoop summary table
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 5. Drug perturbation and OncoTreat analysis A. Summary of drugs and concentrations used B. Drug perturbation data for DU145 C. OncoTreat for drugs to SU2C patients using DU145 D. OncoTreat for drugs to GEMMs using DU145
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 5. Drug perturbation and OncoTreat analysis A. Summary of drugs and concentrations used B. Drug perturbation data for DU145 C. OncoTreat for drugs to SU2C patients using DU145 D. OncoTreat for drugs to GEMMs using DU145
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Detailed Materials and Methods from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Detailed Materials and Methods
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessDetailed Materials and Methods from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Detailed Materials and Methods
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 1: Phenotypic analysis of the GEMMs
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 1: Phenotypic analysis of the GEMMs
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 4: OncoMatch A. OncoMatch TCGA B. OncoMatch SU2C
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 4: OncoMatch A. OncoMatch TCGA B. OncoMatch SU2C
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 3: Transcriptomic analyses of the human patient samples A. TCGA Interactome B. SU2C Interactome C. Protein activity TCGA D. Protein Activity SU2C
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 3: Transcriptomic analyses of the human patient samples A. TCGA Interactome B. SU2C Interactome C. Protein activity TCGA D. Protein Activity SU2C
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 7. Transcriptomic analyses of the PDX models A. PDX interactome B. OncoTreat for drugs to PDX using DU145 cell perturbation data
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 7. Transcriptomic analyses of the PDX models A. PDX interactome B. OncoTreat for drugs to PDX using DU145 cell perturbation data
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 2: Transcriptomic analyses of the GEMMs A. GEMMs Interactome B. Protein activity C. Cluster analyses D. Pathway analyses
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 2: Transcriptomic analyses of the GEMMs A. GEMMs Interactome B. Protein activity C. Cluster analyses D. Pathway analyses